📊 AVAI Key Takeaways
Investment Thesis
AVAI Bio exhibits severe financial distress with negative stockholders' equity of -$2.8M, indicating the company is technically insolvent. The company is burning cash at an unsustainable rate (-$959K operating cash flow) while generating minimal revenue ($276.3K) with negative gross margins, suggesting fundamental business model failure.
AVAI Strengths
- Minimal debt obligations provide some operational flexibility
- Early-stage company status may allow for strategic pivots
- Positive revenue generation exists despite losses
AVAI Risks
- Negative stockholders' equity indicates technical insolvency and imminent going concern issues
- Severe liquidity crisis with current ratio of 0.02x and only $50.4K cash against $3.0M liabilities
- Catastrophic unit economics with -$3.46 of cash burn for every $1 of revenue generated
- Negative gross margins indicate products/services are losing money at point of sale
- Unsustainable cash burn rate of -$959K with current cash reserves lasting approximately 2 weeks
Key Metrics to Watch
- Cash runway and path to profitability or capital raise
- Revenue growth trajectory and gross margin improvement
- Monthly cash burn rate and covenant compliance status
AVAI Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
AVAI Profitability Ratios
AVAI vs Technology Sector
How AVAI BIO, INC. compares to Technology sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
AVAI Balance Sheet & Liquidity
AVAI 5-Year Financial Trend
5-Year Trend Summary: AVAI BIO, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
AVAI Growth Metrics (YoY)
AVAI Capital Allocation
AVAI SEC Filings
Access official SEC EDGAR filings for AVAI BIO, INC. (CIK: 0001740797)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AVAI
What is the AI rating for AVAI?
AVAI BIO, INC. (AVAI) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are AVAI's key strengths?
Minimal debt obligations provide some operational flexibility. Early-stage company status may allow for strategic pivots.
What are the risks of investing in AVAI?
Negative stockholders' equity indicates technical insolvency and imminent going concern issues. Severe liquidity crisis with current ratio of 0.02x and only $50.4K cash against $3.0M liabilities.
What is AVAI's revenue and growth?
AVAI BIO, INC. reported revenue of $276.3K.
Does AVAI pay dividends?
AVAI BIO, INC. does not currently pay dividends.
Where can I find AVAI SEC filings?
Official SEC filings for AVAI BIO, INC. (CIK: 0001740797) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AVAI's EPS?
AVAI BIO, INC. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.